Clinical Trials
15 trialsNCT04984837 2026-06-04
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
NCT05377827 2026-05-06
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
Phase 1 Active not recruiting
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT06362148 2026-05-01
CIRCULATE
University of Aarhus
Active not recruiting
NCT02732275 2026-04-28
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
Phase 1 Active not recruiting
NCT05403450 2026-02-23
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Taiho Oncology, Inc.
Phase 1 Active not recruiting
NCT06089941 2026-02-20
PTCL-SEQ
Centre Henri Becquerel
Active not recruiting
NCT06485219 2026-02-06
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Active not recruiting
NCT04703192 2025-12-09
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Daiichi Sankyo
Phase 2 Active not recruiting
NCT02223208 2025-12-02
FIL_PTCL13
Fondazione Italiana Linfomi - ETS
Phase 1/2 Active not recruiting
NCT04668690 2025-05-31
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Active not recruiting
NCT04072458 2025-02-24
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings, Inc.
Phase 1 Active not recruiting
NCT06550336 2024-08-29
A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).
The First Hospital of Jilin University
Phase 2 Active not recruiting
NCT05749549 2024-08-07
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Shanghai Blueray Biopharma Co., Ltd.
Phase 1/2 Active not recruiting
NCT04526834 2023-04-20
CERTAIN
Tessa Therapeutics
Phase 1 Active not recruiting